RecruitingNCT06827132

Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer

A Non-interventional Study Evaluating Samples From Patients With Suspected Non-small Lung Cancer or Breast Cancer to Describe Pathology Practices and to Evaluate Computational Pathology Plus Artificial Intelligence Algorithms.


Sponsor

AstraZeneca

Enrollment

600 participants

Start Date

Oct 25, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

A multinational observational study to evaluate the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer.


Eligibility

Inclusion Criteria1

  • \-

Exclusion Criteria4

  • Samples with the inadequate technical quality of slides (pre-analytics quality) or images, e.g., broken slides, large out-of-focus areas, slides with fixation artefacts.
  • Samples from cases that were included in the training or technical validation.
  • Sample taken by fine needle aspiration.
  • Sample sent for cytological evaluation.

Locations(1)

Research Site

Nairobi, Kenya

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06827132


Related Trials